Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

Tissue Regenix adds sales specialist for US orthopaedic drive

Distin is a specialist in building sales through targeted marketing and has worked for a number of other US companies.
Tissue Regenix adds sales specialist for US orthopaedic drive
Knee cartilages are expected to be approved by end of 2016

Tissue Regenix (LON:TRX)  has strengthened the management of its US operation with the appointment of Drew Distin to its new orthopaedic subsidiary.

Distin is a specialist in building sales through targeted marketing and has worked for a number of other US companies.

His remit is to plan the launch Tissue Regenix’s new range of orthopaedic products on the US.

Clinical trials are currently ongoing in Europe for OrthoPure XM (porcine meniscus) and OrthoPure XT (porcine tendon) products, with the a target a CE mark for the XM knee cartilage by the end of 2016.

In the US, Tissue will initially focus on  human tissue applications, initially starting with the human tendon (OrthoPure HT).

Tissue Regenix is currently in partnership with tissue bank Community Tissue Services (CTS) for the manufacturing of its wound care product DermaPure.

Peter Hamer, Tissue Regenix Orthopaedic’s commercial director, said Distin brings a wealth of experience.

“This is a very exciting time for Orthopaedics at Tissue Regenix as we continue enrolment of our OrthoPure XT clinical trial and await submission for the CE mark with OrthoPure XM.

“We are on course to complete these tasks within the timeline predicted."

PhilW.jpg
Why Invest In Tissue Regenix Group PLC? Read More Here

Register here to be notified of future TRX Company articles
View full TRX profile

Tissue Regenix Group PLC Timeline

Related Articles

shutterstock_327930536.jpg
May 19 2016
Life sciences firm ValiRx is poised for a busy year ahead as it progresses its lead drugs...
Test-tubes_opt_56d69b8aa24bf.jpg
March 02 2016
The company's results reveal a company in rude health - and one still on the acquisition trial.
immupharma-_kiss_pic_with_mum.png
March 01 2016
Lupuzor is not the only part of the Immupharma story and McCarthy plans also to raise the profile of the rest of the group's early stage pipeline in 2016.....

© Proactive Investors 2016

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.